Orexo has appointed Peter Edman as its new Chief Scientific Officer, responsible for the company’s research and development division.
Peter currently works as CSO and Head of Research and Development at Sobi (Swedish Orphan Biovitrum).
Anders Lundström, President and CEO of Orexo, said: “Peter Edman has extensive experience in the areas of research and development and leadership. Both his skills in early drug discovery and drug development in late stages will be of great value to Orexo.”
Peter has previously held positions within R&D at Pharmacia and AstraZeneca.
He commented: “It will be very exciting and rewarding to develop Orexo’s projects into innovative new drugs that can address significant medical needs.”